Intuitive Biosciences, Inc. is pleased to announce its agreement to acquire the animal health and research tools assets and businesses of Gentel Biosciences. Intuitive is focused on serological tests for animal health and research and testing tools for the pharmaceutical, CRO, and academic research markets. The acquisition of Gentel’s products for testing non-human primates, including the Colony Surveillance Assays and a ground-breaking screening test for tuberculosis, is consistent with Intuitive’s strategy to grow its line of diagnostic products for the research animal market. “I would like to welcome Gentel’s scientific staff to Intuitive Bio. We are fortunate to have such a highly skilled and motivated group of scientists join our team,” said Shawn Guse, President and CEO of Intuitive Bio.
The terms of the transaction were not disclosed. The transaction is expected to close in the second quarter of 2012.
